Abstract
Pulmonary hypertension is a rapidly progressive, life-threatening, and often fatal disease. Despite many new developments in pulmonary arterial hypertension (PAH) therapy, there is currently no cure for PAH, and new therapies are desperately needed. PAH pathobiology involves a remodeling process in pulmonary arteries that plays a critical role in elevating pulmonary arterial and right ventricle pressures. The discovery and development of new therapies requires animal models of PAH that mimic the human disease, including vascular remodeling.
Here we review and describe a detailed protocol for creating an in vivo model of Sugen/Hypoxia-induced PAH in mice that is commonly used to assess the efficiency of new therapies in PAH. Severe pulmonary hypertension can be established in 1 month using this protocol. Additional protocols to evaluate the model by invasive pressure measurements and histology are provided.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Galiè N, Humbert M, Vachiery J-L et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119
Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425–1436
Wilcox SR, Kabrhel C, Channick RN (2015) Pulmonary hypertension and right ventricular failure in emergency medicine. Ann Emerg Med 66:619–628
Simon MA, Pinsky MR (2011) Right ventricular dysfunction and failure in chronic pressure overload. Cardiol Res Pract 2011:568095
Dorfmüller P (2013) Pulmonary hypertension: pathology. Handb Exp Pharmacol 218:59–75
Guignabert C, Dorfmüller P (2017) Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med 38:571–584
Huertas A, Perros F, Tu L et al (2014) Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation 129:1332–1340
Herve P, Humbert M, Sitbon O et al (2001) Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 22:451–458
Jonigk D, Golpon H, Bockmeyer CL et al (2011) Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 179:167–179
Pietra GG, Edwards WD, Kay JM et al (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80:1198–1206
Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117
Voelkel NF, Tuder RM (2000) Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Investig 106:733–738
Stenmark KR, Meyrick B, Galiè N et al (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Phys Lung Cell Mol Phys 297:L1013–L1032
Bauer NR, Moore TM, McMurtry IF (2007) Rodent models of PAH: are we there yet? Am J Phys Lung Cell Mol Phys 293:L580–L582
Taraseviciene-Stewart L, Kasahara Y, Alger L et al (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:427–438
Abe K, Toba M, Alzoubi A et al (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747–2754
Ciuclan L, Bonneau O, Hussey M et al (2011) A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184:1171–1182
Vitali SH, Hansmann G, Rose C et al (2014) The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. Pulm Circ 4:619–629
Sakao S, Tatsumi K (2011) The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 81:253–261
Acknowledgments
This work was supported by grants from the American Heart Association (AHA-17SDG33370112) to Y.S., from the National Institutes of Health R01HL133554 to L.H, and from the R01 HL117505, HL 119046, HL129814, 128072, HL131404, R01HL135093, a P50 HL112324, and two Transatlantic Fondation Leducq grants to R.J.H.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bueno-Beti, C., Hadri, L., Hajjar, R.J., Sassi, Y. (2018). The Sugen 5416/Hypoxia Mouse Model of Pulmonary Arterial Hypertension. In: Ishikawa, K. (eds) Experimental Models of Cardiovascular Diseases. Methods in Molecular Biology, vol 1816. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8597-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8597-5_19
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8596-8
Online ISBN: 978-1-4939-8597-5
eBook Packages: Springer Protocols